PDSB · PDS Biotechnology Corporation
AI read · Neutral
The AI's read
PDSB dumped about 67% after announcing a strategic refocus onto PDS0301 for metastatic colorectal cancer and said PDS0101 could be preserved via partnership. Shares hit a new 52-week low on heavy volume. The market has already repriced the story, with the stock trading near $0.25 and a sub-$14M market cap. Technicals are oversold but a prior death cross and collapsing SMAs keep downward pressure without new catalysts. We lean neutral. The headline hurt badly and raised binary clinical and cash risks, but much of the downside appears priced in until the company lays out runway or a clear partnership plan.